Faruqi & Faruqi wins appeal in First Circuit, In re LoEstrin 24 FE Antitrust Litigation.


The United States Court of Appeals for the First Circuit reversed the grant of a motion to dismiss a complaint alleging a violation of the Sherman Act arising from a reverse payment agreement in a pharmaceutical patent litigation, In re LoEstrin 24 FE Antitrust Litigation.  The First Circuit held that an agreement by a brand pharmaceutical company to delay launching its own authorized generic of LoEstrin 24 Fe, and thus not compete against a generic company in exchange for an agreement by the generic company to quit its challenge to the brand patent and to delay its entry into the market, can constitute a large reverse payment in violation of the Sherman Act.  The case has been remanded to the United States District Court for the District of Rhode Island.   Faruqi & Faruqi is co-lead counsel in the matter on behalf of a putative class of direct purchasers.

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

1901 Avenue of the Stars Suite 1060
Los Angeles, California 90067
(424) 256-2884
(424) 256-2885

Georgia

3565 Piedmont Road NE Building Four, Suite 380
Atlanta, Georgia 30305
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania